Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06538844
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-01
Brief Title:
Albumin for Patients With Acute Large Vessel Occlusive Stroke Undergoing Endovascular Reperfusion Therapy
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Albumin for Patients With Acute Large Vessel Occlusive Stroke Undergoing Endovascular Reperfusion Therapy
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of this study is to evaluate the effectiveness and safety of endovascular therapy combined with 25 human albumin in the treatment of acute large vessel occlusive stroke
Detailed Description:
Stroke is the second leading cause of death worldwide 85 of which are acute ischemic strokes AIS Neuronal death is the primary pathological manifestation of acute ischemic stroke AIS Preclinical studies have revealed that neuroprotective agents can reduce neuronal damage and improve neurological outcomes in experimental animals However over the past 40 years clinical translation of neuroprotective drugs has consistently failed In 2015 with the publication of five randomized controlled trials RCTs on thrombectomy for anterior circulation there was sufficient evidence-based support for thrombectomy in large vessel occlusion of the anterior circulation ushering us into a new era of AIS treatment - the era of efficient reperfusion therapy In this context neuroprotective therapy should be re-examined as an adjunctive approach to reperfusion therapy
Albumin the predominant plasma protein synthesized primarily in the liver possesses various biochemical properties that are expected to confer a neuroprotective effect following acute ischemic stroke
This study is a multi-center randomized double-blind placebo-controlled clinical study focusing on patients with acute large vessel occlusive stroke It aims to investigate the effectiveness and safety of albumin as an adjunctive treatment to endovascular therapy compared with placebo in reducing infarct volume improving long-term functional outcomes and daily living activities of patients with acute ischemic stroke in the era of reperfusion therapy
Albumin the predominant plasma protein synthesized primarily in the liver possesses various biochemical properties that are expected to confer a neuroprotective effect following acute ischemic stroke
This study is a multi-center randomized double-blind placebo-controlled clinical study focusing on patients with acute large vessel occlusive stroke It aims to investigate the effectiveness and safety of albumin as an adjunctive treatment to endovascular therapy compared with placebo in reducing infarct volume improving long-term functional outcomes and daily living activities of patients with acute ischemic stroke in the era of reperfusion therapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None